{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:37:15Z","timestamp":1787960235181,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.amjcard.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T17:21:58Z","timestamp":1718212918000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease"],"prefix":"10.1016","volume":"225","author":[{"given":"Nader","family":"Mankerious","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Toelg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"de la Torre Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell W.","family":"Krucoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Spirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem M.","family":"Chehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kunadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Maksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Picon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Sardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Varenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Richardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.06.003_bib0001","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2020.06.085","article-title":"Trial design principles for patients at high bleeding risk undergoing PCI: JACC scientific expert panel","volume":"76","author":"Capodanno","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002427","article-title":"Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents","volume":"8","author":"Koppara","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0003","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"XIENCE 90 and XIENCE 28 Investigators. 3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0004","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjcvp\/pvad032","article-title":"Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease","volume":"9","author":"Valgimigli","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0006","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2021.08.074","article-title":"Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI","volume":"78","author":"Valgimigli","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2007.04.051","article-title":"Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry","volume":"50","author":"Machecourt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0008","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000441-200304000-00002","article-title":"Cardiovascular mortality in end-stage renal disease","volume":"325","author":"Collins","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014294","article-title":"Blood coagulation system in patients with chronic kidney disease: a prospective observational study","volume":"7","author":"Huang","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0010","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0011","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0012","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ccd.26921","article-title":"Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: an analysis from the PRODIGY trial","volume":"90","author":"Gargiulo","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0013","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting","volume":"69","author":"Palmerini","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ahj.2020.09.019","article-title":"Design and rationale of the XIENCE short DAPT clinical program: an assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent","volume":"231","author":"Valgimigli","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0015","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0016","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0017","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0018","first-page":"e4","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0019","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jcin.2016.04.009","article-title":"Time-dependent associations between actionable bleeding, coronary thrombotic events, and mortality following percutaneous coronary intervention: results from the Paris registry","volume":"9","author":"Baber","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","article-title":"Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis","volume":"156","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019630","article-title":"Factors related to major bleeding after ticagrelor therapy: results from the TICO trial","volume":"10","author":"Cho","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0023","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12928-020-00651-9","article-title":"STOPDAPT-2 Investigators. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial","volume":"36","author":"Watanabe","year":"2021","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0025","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255645","article-title":"Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease","volume":"16","author":"Kao","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0027","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.kint.2016.09.014","article-title":"Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease","volume":"91","author":"Carrero","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0028","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2215\/CJN.12901018","article-title":"Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis","volume":"14","author":"Mavrakanas","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2024.06.003_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2022.04.004","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: a systematic review and meta-analysis","volume":"250","author":"Garg","year":"2022","journal-title":"Am Heart J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924004259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924004259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T05:31:51Z","timestamp":1722317511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924004259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"alternative-id":["S0002914924004259"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.06.003","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}